Stockholm, Sweden, June 9, 2011
Elekta’s strategy will result in accelerated revenue growth and continued strong EBIT growth. This was the message from Tomas Puusepp, President and CEO at today’s Capital Markets Day.
Following the release of Elekta’s year-end report for 2010/11, Tomas Puusepp described how Elekta is well positioned to drive growth in several areas. “Our first priority is to accelerate growth from delivering systems to solutions.” He says Elekta can increase market share in established markets through extended solutions while investing in emerging markets to capture growth opportunities. Puusepp also said that strategic acquisitions could support growth areas.
“Our second priority is to increase margins and establish industry-leading efficiency. This includes improving G&A efficiency and driving higher margins by continuing to increase our sales in services and software,” he said.
Puusepp revealed Elekta’s strategy for sustainable profitable growth for the coming years. In 2015 Elekta is foreseen to reach a revenue growth of 13-15 percent. EBIT, earnings before interest and tax, is expected to show continued strong growth, helped by a decrease in SG&A from 22 to 19 percent of net sales. Earnings per share is expected to have shown an increase by more than 60 percent in year 2015 and net debt to equity is expected to be below 0.5.
The Capital Markets Day is held on June 9 from 09.00 CET to 12.00 CET, at the Museum of Modern Art in Stockholm. A webcast from the event will be available on Elekta’s website (www.elekta.com).
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow-enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that give confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible today.Today, Elekta solutions in oncology and neurosurgery are used in more than 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group. Elekta employs about 2,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb